Drugs / SUPLEXA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05237206 | Apr 2022 → Jul 2024 | — | Alloplex Biotherapeutics Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUPLEXA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05237206 ↗ |
| Route | Intravenous | “repeated intravenous (IV) infusions of SUPLEXA monotherapy” NCT05237206 ↗ |